Subsequent Events	6 Months Ended
Sep. 30, 2026
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On October 1, 2026 the Company announced the commercial availability of TUDRIQEV in the United States. Healthcare providers began ordering TUDRIQEV for next day delivery on October 2, 2026. TUDRIQEV is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Subsequent Events

6 Months Ended

Sep. 30, 2026

On October 1, 2026 the Company announced the commercial availability of TUDRIQEV in the United States. Healthcare providers began ordering TUDRIQEV for next day delivery on October 2, 2026. TUDRIQEV is indicated in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen. This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).